Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program.